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Abstract Due to the complexity of typical metabolomics
samples and the many steps required to obtain quantitative
data in GC 9 GC–MS consisting of deconvolution, peak
picking, peak merging, and integration, the unbiased non-
target quantification of GC 9 GC–MS data still poses a
major challenge in metabolomics analysis. The feasibility
of using commercially available software for non-target
processing of GC 9 GC–MS data was assessed. For this
purpose a set of mouse liver samples (24 study samples and
five quality control (QC) samples prepared from the study
samples) were measured with GC 9 GC–MS and GC–MS
to study the development and progression of insulin
resistance, a primary characteristic of diabetes type 2. A
total of 170 and 691 peaks were quantified in, respectively,
the GC–MS and GC 9 GC–MS data for all study and QC
samples. The quantitative results for the QC samples were
compared to assess the quality of semi-automated
GC 9 GC–MS processing compared to targeted GC–MS
processing which involved time-consuming manual cor-
rection of all wrongly integrated metabolites and was
considered as golden standard. The relative standard
deviations (RSDs) obtained with GC 9 GC–MS were
somewhat higher than with GC–MS, due to less accurate
processing. Still, the biological information in the study
samples was preserved and the added value of GC 9 GC–
MS was demonstrated; many additional candidate bio-
markers were found with GC 9 GC–MS compared to
GC–MS.
Keywords Metabolomics  Comprehensive
two-dimensional gas chromatography mass spectrometry 
GC 9 GC–MS  Automated data processing  Diabetes 
Insulin resistance
1 Introduction
Metabolomics research involves the comprehensive non-
target analysis of all, or at least as many as possible,
metabolites in cells, tissue or body fluids. The complexity of
the metabolome makes this a challenging task for analytical
chemists. For example, samples of the simplest microor-
ganisms already contain, by estimation, several hundreds of
different metabolites. At present, the main analytical tech-
niques used for the analysis of the metabolome are nuclear
magnetic resonance spectroscopy (NMR) and hyphenated
techniques, such as gas chromatography (GC) and liquid
chromatography (LC) coupled to mass spectrometry (MS).
Gas chromatography coupled to mass spectrometry
(GC–MS) is a highly suitable technique for metabolomics
analysis due to the high separation power, reproducible
retention times and sensitive selective mass detection.
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In previous papers a one-dimensional GC–MS method
(Koek et al. 2006) and a comprehensive two-dimensional
gas chromatography mass spectrometry method (GC 9
GC–MS; Koek et al. 2008) suitable for the analysis of a
broad range of small polar metabolites were described
using a derivatization with an oximation reagent followed
by silylation. Several other GC–MS (Fiehn et al. 2000;
Jonsson et al. 2004; Roessner et al. 2000; Strelkov et al.
2004; Villas-Boas et al. 2005) and GC 9 GC–MS
(O’Hagan et al. 2007; Pierce et al. 2006b; Shellie et al.
2005) based methods for metabolomics have been reported.
The principle of GC 9 GC–MS is based on the coupling
of two analytical columns with different selectivities
coupled through a modulator. The so-called dual-stage
cryogenic modulator equipped with four jets (two liquid-
nitrogen cooled and two hot-gas jets) allows for the con-
secutive trapping, cryogenic focussing and release of small
fractions from the first column effluent in narrow bands onto
the second column. In this comprehensive setup, the entire
sample is separated on both columns and no information of
the first separation is lost during the second one. The
resulting GC 9 GC–MS chromatogram consists of a large
series of consecutive second dimension (2D) separations. To
maintain the separation of the first column, each peak eluting
from the first dimension should be sampled, i.e. modulated,
minimally three to four times (Murphy et al. 1998).
GC 9 GC–MS offers several advantages over GC–MS,
i.e. higher chromatographic separation power, a broader
dynamic range and lower detection limits, and should be
the preferred technique for metabolomics analysis. How-
ever, quantification of metabolomics samples using
GC 9 GC–MS is still a major challenge. To get from raw
total-ion chromatographic data to a list of sample compo-
nents with their corresponding peak areas and mass spectra,
many steps are required, including peak finding, decon-
volution, integration and combining of the peaks from
different modulations originating from one compound. The
performances of all the steps are influencing the final data
quality and, consequently, the reliability of the biological
information extracted from the data. In addition, all
metabolites are of interest and need to be quantified. Sev-
eral approaches have been published to process GC 9 GC–
MS data after analysis to find metabolites that distinguish
between samples (Mohler et al. 2008; Pierce et al. 2006a;
Shellie et al. 2001; Sinha et al. 2004), but only few papers
on the quantification of all (or at least as many as possible
peaks) peaks have been published.
Hoggard and Synovec (2008) described a method for
applying PARAFAC to GC 9 GC-TOF-MS data in an
automated fashion that required no assumptions about
analyte identities. They proposed that the method was
applicable as post processing step providing deconvolu-
tion and quantification of all analytes in a sample.
However, their method was very time-consuming, i.e. one
chromatogram had to be divided in numerous subsections,
and complete analysis required, by their estimation, tens of
hours. Oh et al. (2008) developed a peak sorting method
(MSsort) for GC 9 GC–MS data in Matlab. Raw data files
were first processed using the ChromaTOF software
(LECO, St. Joseph, MI, USA) to provide peak tables.
Subsequently, MSsort was used to sort and combine peaks
by utilizing first- (1rT) and second-dimension (
2rT) retention
times and the mass spectrum. However, no quantitative
data were presented in neither of the described papers. To
our knowledge the only attempt for non-target quantifica-
tion of metabolites in a real life metabolomics study was
published by Li et al. (2009). They quantified 692 peaks in
79 human-plasma samples to identify possible biomarkers
for type-2 diabetes mellitus. Quantification was performed
by exporting m/z 73 from the GC 9 GC–MS chromato-
grams and alignment, peak merging and quantification was
performed using their in-house developed software
(GC 9 GC Workstation; Qiu et al. 2007). The repeatability
of the quantification was tested using pooled plasma sam-
ples. The mean relative standard deviations (RSDs) in five
consecutive injections of one plasma sample and five
consecutive injections of five different plasma samples
were 14 and 20%, respectively. It is not fully clear how
many peaks were included in the mean RSD (only peaks
that were quantified in all samples were included). Besides,
the use of a single mass trace (m/z) instead of the decon-
voluted spectrum of a peak for quantification can result in
errors in quantification of coeluting peaks and the assign-
ment of the identity of a peak.
In this paper, the possibilities and limitations of the
software with regard to non-target semi-automated pro-
cessing of GC 9 GC–MS data were evaluated. This was
done by measuring and processing a set of mouse-liver
samples that were part of a larger study investigating the
development of insulin resistance/type-2 diabetes mellitus
(DM2) (Kleemann et al. 2010). DM2 is a multifactorial
complex disease associated with metabolic deregulations.
Despite major efforts, the pathophysiological mechanisms
underlying the beginning and progression of the disease are
still incompletely understood. Identification of changes in
hepatic metabolite profiles can help to identify dysregu-
lated metabolic pathways in DM2 and thus in the selection
of (new) therapeutic regimens. Mice with a humanized
lipoprotein metabolism, APOE*3Leiden transgenic (E3L)
mice (Zadelaar et al. 2007) were used and mice were fed a
high-fat diet known to induce insulin resistance/DM2.
Livers were collected at different time points during
12 weeks of high-fat-diet feeding. The samples were
measured with GC 9 GC–MS and with GC–MS to be
able to compare the results from both methods. Results of
semi-automated GC 9 GC–MS data processing were
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compared with a fully optimized, but labour-intensive,
targeted GC–MS data processing method used in our lab,
involving the inspection and, if required, manual correction
of the integration of all quantified metabolites. In addition,
time-resolved changes in metabolic profiles of the mouse
livers were identified using principal-component analysis
(PCA) and principal-component-discriminant analysis
(PCDA).
2 Experimental
2.1 Chemicals and materials
Pyridine (Baker analyzed) was purchased from Mallinkrodt
Baker (Deventer, The Netherlands) and pyridine hydro-
chloride (analytical grade) was purchased from Sigma-
Aldrich (Zwijndrecht, The Netherlands). A solution of
56 mg/ml ethoxyamine hydrochloride ([99%, Acros
Organics, Geel, Belgium) in pyridine was used for oximation
and N-methyl-N-trimethylsilyl trifluoroacetamide (MSTFA;
Alltech, Breda, The Netherlands) was used for silylation.
2.2 Standards
Standards used as quality-control standards, leucine-d3,
glutamic acid-d3, phenylalanine-d5, glucose-d7, alanine-d4
and cholic acid-d4, were purchased from Spectra Stable
Isotopes (Columbia, USA). 4,4-Difluorobiphenyl, trifluo-
roantracene and dicyclohexyl phthalate were purchased
from Sigma-Aldrich. Three internal standard (IS) mixtures
were prepared; IS mix 1 containing leucine-d3 (250 ng/ll),
glutamic acid-d3 (250 ng/ll), phenylalanine-d5 (250 ng/
ll), glucose-d7 (250 ng/ll) in water, IS mix 2 containing
alanine-d4 (250 ng/ll) and cholic acid-d4 (250 ng/ll) in
pyridine, and IS mix 3 containing 4,4-difluorobiphenyl
(250 ng/ll), trifluoroantracene (250 ng/ll) and dicyclo-
hexyl phthalate (250 ng/ll) in pyridine.
2.3 Mouse-liver samples
Animal experiments were approved by the Institutional
Animal Care and Use Committee of The Netherlands
Organization for Applied Scientific Research (TNO) and
were in compliance with European-Community specifica-
tions regarding the use of laboratory animals. Male
ApoE*3Leiden transgenic (E3L) mice subjected to high fat
diet feeding essentially as specified in Kleemann et al.
(2010). Briefly, E3L mice displaying a humanized lipo-
protein metabolism and lipid profile and sensitive to high
fat diet treatment (Kleemann et al., 2007) were fed a high-
fat diet containing 24% beef tallow (HF diet; Hope Farms,
Woerden, The Netherlands) and were euthanized with
CO/CO2 after zero weeks (n = 8), 6 weeks (n = 8) and
12 weeks (n = 8) of high-fat diet feeding.
Livers were collected at sacrifice and were snap-frozen
immediately in liquid nitrogen, and stored at -80C until
use (no longer than 10 months).
2.4 Sample preparation
The liver samples were freeze-dried overnight and
homogenized. 10-mg aliquots of the liver samples were
weighed and placed inside a 2-ml Eppendorf tube. After
addition of 10 ll of IS mix 1 and 500 ll of methanol/water
4:1 v/v, all samples were sonificated for 30 min and sub-
sequently centrifuged for 10 min at 140869g (10000 rpm).
The supernatants were transferred to autosampler vials and
subsequently dried under nitrogen flow. Then 10 ll IS mix
2 and 30 ll ethoxyamine hydrochloride solution were
added and the samples were oximated for 90 min at 40C on
a tube roller mixer placed inside an oven. Subsequently,
10 ll of IS mix 3 and 100 ll of MSTFA were added and the
samples were silylated for 50 min at 40C on a tube roller
mixer inside an oven. Finally, the samples were centrifuged
for 20 min at 20819g (3500 rpm) prior to injection.
2.5 Quality-control (QC) sample
A pooled sample of six different liver samples from dif-
ferent time points (two per time point) was used as QC
sample. The samples were prepared according to the
sample preparation described above; however, after
extraction the supernatants of all samples were mixed and
subsequently divided over ten separate autosampler vials.
Furthermore, the amounts of liver sample and IS-mix were
adjusted to obtain the same amount of biomass and internal
standards in the QC samples compared to the study
samples.
2.6 GC–MS analysis
The derivatized extracts were analyzed with an Agilent
6890 gas chromatograph coupled with an Agilent 5973
mass-selective detector (Agilent technologies, Santa Clara,
CA, USA). 1-ll aliquots of the extracts were injected into a
DB5-MS capillary column (30 m 9 250 lm I.D., 0.25 lm
film thickness; J&W Scientific, Folson, CA, USA) using
PTV-injection (Gerstel CIS4 injector; Mu¨lheim an der
Ruhr, Germany) in the splitless mode. The temperature of
the PTV was 70C during injection and 0.6 min after
injection the temperature was raised to 300C at a rate of
2C/s and held at 300C for 20 min. The initial GC oven
temperature was 70C, 5 min after injection the GC-oven
temperature was increased with 5C/min to 320C and held
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for 5 min at 320C. Helium was used as a carrier gas, and
pressure programmed such that the helium flow was kept
constant at a flow rate of 1.7 ml per min. Detection was
achieved using MS detection in electron ionisation and
full-scan monitoring mode (m/z 15–800). The temperature
of the ion source was set at 250C and that of the quad-
rupole at 200C.
2.7 GC 9 GC–MS analysis
The derivatized samples were analyzed with an Agilent
6890 gas chromatograph fitted with a dual-stage, four-jet
(two liquid-nitrogen cooled and two hot-gas jets) cryogenic
modulator and a secondary oven (LECO) and coupled to a
time-of-flight mass spectrometer (Pegasus III, LECO). The
configuration of the first (1D) and second dimension (2D)
column and the method parameters were optimized, as
described in Koek et al. (2008).
A 30 m 9 0.25 mm I.D. 9 0.25 lm forte BPX-50 col-
umn (SGE, Milton Keynes, UK) was used as the 1D col-
umn and a 2 m 9 0.32 mm I.D. 9 0.25 lm forte BPX5
column (SGE Europe) was used as the 2D column.
1-ll aliquots of the derivatized extracts were injected
using PTV-injection (Gerstel CIS4) in the splitless mode.
The temperature of the PTV was 70C during injection and
0.6 min after injection the temperature was raised to 300C
at a rate of 2C/s and held at 300C for 20 min. The initial
GC-oven temperature was 70C, 3 min after injection the
temperature was raised to 300C with a rate of 5C/min and
held at 300C for 10 min. The temperature offset of the
secondary oven and modulator compared to the GC oven
were set at ?30 and ?40C, respectively. The modulation
time was 6 s, with the hot-pulse time set at 1 s. Helium was
used as carrier gas and the analyses were carried out in
constant-pressure mode at 300 kPa. The MS transfer line
was set at 325C and the ion-source temperature was
280C. The detector voltage was set at -1600 V and the
data acquisition rate was 75 Hz.
2.8 Data processing GC–MS
The Chemstation software (Version E02.00.493, Agilent
Technologies) was used for processing of the data. A target
table was constructed using an in-house library containing
the mass spectra and retention times of over 600 reference
metabolites (authentic standards), over 100 annotated
metabolites (spectral match with NIST library) and over
200 unknown metabolites commonly found in blood
products. Furthermore, metabolites (known or unknown)
specific for this study were added to the target table. A total
of 175 targets were found in the QC samples (total of three)
and quantified in all samples by reconstructing an ion
chromatogram of a specific mass from the mass spectrum
of the target. The quantification for all targets was manu-
ally checked by visual control and if necessary peak inte-
gration was corrected manually.
2.9 Optimization of GC 9 GC–MS data processing
ChromaTOF software V3.35 was used for data processing.
During the optimization step the following parameters
were varied separately in the processing method: first
dimension peak width (1wB) (30, 60, 90 and 120 s), second
dimension peak width (2wB) (0.1, 0.15, 0.2, 0.3 and 0.4 s),
smoothing factor (auto, 3, 5, 7) and the match required to
combine different 2D peaks originating from one entry
(400–800). The different processing methods were evalu-
ated by investigating the deconvoluted mass spectra, the
integration and the combining of the 2D peaks of the IS.
For all IS, except for cholic acid-d4, the naturally-occur-
ring non-labelled form was also detected in the sample and
partly coeluted with the labelled IS. These naturally-
occurring compounds (except for glucose that was present
in extremely high concentration) were also evaluated to
check the performance of the deconvolution. The IS and
naturally-occurring metabolites were distributed over the
entire chromatogram and eluted at 1rT between 356 and
2846 s and 2rT between 2.4 and 5 s. The
2wB and the match
required to combine 2D peaks were the primary parameters
determining the quality of the deconvolution (2wB) and the
combining of the different 2D peaks from one peak (both
parameters). Unfortunately, it is not possible to set differ-
ent 2wB in the software for different
2rT, because metabo-
lites eluting at high 2rT, e.g. cholic acid-d4, were better
quantified with broader peak widths than metabolites
eluting at low 2rT. In our case study, the
2wB was best set
somewhat narrower (0.15 s) than the actual peak width of
the narrowest peaks of interest (0.2 s baseline).
2.10 Data processing for GC 9 GC–MS
A computer with the following specifications was used:
Pentium [R] dual Intel processor CPU 3.4 GHz, 3 GB
RAM, hard disk: Serial ATA, 7200 RPM, 16 MB cache,
RAID 24/7 (Seagate Barracuda ES, 3.0 GB/s, 500 GB). All
samples were processed with ChromaTOF V3.35 software
with the following settings. Baseline tracking: default;
baseline offset: 1.0; peak width: 0.15 s; segmented pro-
cessing: peak find S/N 20, number of apexing masses 2;
GC 9 GC parameters: match required to combine 500,
peak width 90 s, mass threshold 0. Quantification for every
individual entry was performed on their unique mass in the
mass spectrum determined by the ChromaTOF software.
The peaks from the constructed calibration table were
quantified in all QC and study samples.
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2.11 Construction of calibration table for
GC 9 GC–MS
One of the QC samples from the middle of the sequence
was processed with the method described above, except the
peak find S/N was set to 200. As many artefact peaks as
possible were removed. For example, all peaks related with
solvents and reagents (eluting at low 2rT) and multiple
entries from highly concentrated tailing metabolites (i.e.
phosphate). All remaining entries were added to a cali-
bration table. Targets from the 1D-GC–MS target table that
were unambiguously identified in the 2D-GC 9 GC–MS
data, i.e. the identity was confirmed by the injection of a
authentic standard or the mass spectrum of the metabolite
was considered unique, were renamed (total 107 targets) in
the 2D calibration table. The maximum 1rT deviation in the
calibration table was set to 13 s for every entry. The
retention time deviation was set to 0.1 s, the minimum area
threshold was 0, the match threshold was 550 and the S/N
threshold was set to 5.
2.12 Post processing of GC 9 GC–MS
The quantitative data for all 1025 targets in the calibration
table were exported to Excel. Compounds that were not
found in more than one QC sample were removed (825
entries left). Subsequently, entries with more than four
blank values in all samples were removed from the data set
(691 entries left excl. internal standards). Of course, a
blank value can be obtained when the concentration of the
metabolite is below the limit of detection. However, in
many occasions blank values were obtained even when the
peak of interest was present in the sample (further referred
to as a missing value), due to a low spectrum match. A low
match was mostly caused by mistakes in the deconvolution
either in the sample itself or in the sample used for the
construction of the calibration table. However, the use of a
selective mass from the mass spectrum for every metabo-
lite (as defined in the reference table of the selected QC
sample), still allows the quantification of wrongly decon-
voluted peaks, although the reliability is lower. To fill the
remaining missing values in the data set (total of 169 blank
values), the chromatograms were reprocessed with a match
threshold in the calibration table of 200 rather than 500. In
this way the missing values for peaks that were unassigned
due to a low match factor could be filled from the newly
processed data. Of course, only correct assignments of
these missing peak areas (as manually controlled via cor-
rect mass spectrum and retention time) were filled from the
newly processed data. Then, all remaining peaks with
missing values in the QC and/or study samples were
checked and corrected manually by assigning the right
peak in the chromatogram to the compound in the
calibration table. The integration of the peaks and the
combining of 2D peaks were not corrected as this was
extremely time-consuming and therefore considered an
unrealistic option.
3 Results and discussion
The present study was directed at performing and opti-
mizing non-target data processing for GC 9 GC–MS. A
set of 29 mouse liver samples was analyzed with both GC–
MS and GC 9 GC–MS. The same set of samples were
analyzed with both systems, both systems used identical
injectors, injection methods and gas chromatographs.
Therefore, the variability in the RSDs of internal standards
and QC samples was caused by later stages of the analyt-
ical process (i.e. GC temperature ramp, second-dimension
GC separation versus no second-dimension GC separation,
detection and processing). Ideally, the same detectors
should be used to compared one-dimensional and two-
dimensional processing. However, in our experience the
Chemstation software allows a more precise quantification
in one-dimensional processing than can be achieved with
the ChromTOF software, e.g. due to (i) the possibility to set
integration parameters for individual peaks, (ii) the ability
to use qualifier masses (define ratios between masses that
should be fulfilled to assign a target) and (iii) the absence
of an automated deconvolution process. Therefore, we used
an Agilent GC-quadrupole MS system for this comparative
study (and the majority of metabolomics studies in our
lab), even though the time-of-flight mass spectrometer is
more sensitive.
The fully optimized GC–MS processing method had a
targeted approach (see Sect. 2). All 170 quantified
metabolites in all samples were automatically integrated,
the integration results visually inspected and wrongly
integrated peaks were manually corrected. The non-tar-
geted GC 9 GC–MS data processing method was semi-
automated, i.e. the construction of the target table and
assignment of missing values required manual interaction;
however, the integration of peaks or mistakes in the
combination of peaks from the same entry were not cor-
rected to reduce the processing time. The data-processing
times and results for GC–MS and GC 9 GC–MS were
compared. Furthermore, the general data quality of the
GC 9 GC–MS analyses was investigated. Finally, the
results obtained with the liver samples using GC–MS and
GC 9 GC–MS were analyzed using multivariate statistics
(PCA/PCDA) in order to identify time-resolved metabolite
patterns. These data may provide biomarkers for the
development and progression of insulin resistance/DM2
and insight into the metabolic dysregulations underlying
the disease process.
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3.1 Comparison of time required for processing
of GC–MS and GC 9 GC–MS data
The workflow for the GC 9 GC–MS processing is shown in
Table 1. In total approximately 50 h of analyst time were
required to optimize the processing and subsequently pro-
cess the entire data set of 29 samples. Furthermore approx-
imately 61 h of computer time were needed for the
processing. The processing of the data files with the com-
puter was mostly done overnight, so that the optimization
and processing of the data set could be performed within
about 2 weeks. The GC–MS processing required about 40 h
of analyst time; 25 h for the construction of the target table
(including finding the targets by using the in-house database
of commonly found metabolites, searching new targets in
this specific study and adjusting integration parameters for
individual metabolites) and 15 h for the processing of one
batch and eventual correction of the integration of metabo-
lites from the calibration table. Both processing methods are
quite time consuming, especially for the GC 9 GC–MS
data, requiring 25% more analyst time compared to GC–MS
processing. However, the optimization and construction of
the target table takes a relatively long time, and every extra
batch of about 30 samples will take approximately 20 and
10 h of analyst time for, respectively, 2D and 1D-process-
ing. For the GC 9 GC–MS processing, the assignment of
the missing values is very time consuming (Table 1, step 8),
even though we used a strategy to fill the missing values by
reprocessing the data with a very low match threshold of 200
in the calibration table (cf. Sect. 2.12). This strategy
decreased the required analyst time for this step (Table 1,
step 8) with approximately 30–50% from 30 h to about
15–20 h per batch. However, one major bottleneck in the
processing was the speed of the software in combination
with the computer speed. Due to the large data files obtained
with GC 9 GC–MS every action performed in the software
is very slow, e.g. loading of a data file, selection of an
assigned peak in the calibration table and the assignment of a
peak to an entry in the calibration table and especially the
correction of wrongly integrated and combined modulations
from one entry. So even if no manual corrections are per-
formed, the checking of the data is already very time-con-
suming. This might be improved using a faster computer,
however, it is expected that the gain in speed will be limited.
Probably, more efficient algorithms are required to improve
the speed significantly. It should be noted that recently a
newer and faster version of the ChromaTOF software (V
4.30) has become available. Most probably the computer
processing time and the time required for the assignment of
the blank values (step 8, Table 1) can be reduced with the
new software.
3.2 Comparing data processing results of one-
dimensional GC–MS with two-dimensional
GC 9 GC–MS
3.2.1 Number of entries
The target table for GC–MS was constructed using a home-
made database with retention times and mass spectra of
over 600 reference metabolites (authentic standards), over
100 annotated metabolites (spectral match with NIST
library) and over 200 unknown metabolites commonly
found in blood products. Additionally, compounds detected
specifically for this study in the QC sample (see Sect. 2)
were added to the target table. A total of 170 targets were
found in the liver samples, some with very low signal-to-
noise ratios (S/N = 3 in reconstructed ion chromatogram
(RIC)). In Table 2 the number of entries above a certain
signal-to-noise ratio in the total ion current (TIC) after
Table 1 Workflow for optimizing and carrying out GC 9 GC–MS data processing
Task Samples Analyst
time (h)
Computer
time (h)
1. Optimize processing method (peak width, smoothing, match required
to combine 2D peaks from one entry)
5 QCs 8 20
2. Processing for construction of target table 1 QC 0 1
3. Construction target table (removing artifacts from, i.e.
solvent and reagents)
1 QC 1 0
4. Find targets from GC–MS in GC 9 GC–MS target table 1 QC 16 0
5. Processing of samples using constructed target table 29 (all) 0 40
6. Copy data to spreadsheet 29 (all) 1 0
7. Removing entries with too many blanks 29 (all) 1 0
8. Assigning peaks of remaining blank valuesa 29 (all) 20 0
Total time required 29 (all) 47 61
a Reprocessing of all the data with a low match factor (200) takes about 20 h of extra computer time
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deconvolution are shown for GC–MS (determined with
AMDIS deconvolution software; Stein 1999) and
GC 9 GC–MS. Due to lower detection limits and higher
peak capacities in GC 9 GC–MS compared with GC–MS,
more possible compounds were detected.
For the construction of the GC 9 GC–MS target table
an S/N cutoff of 200 was chosen. It should be mentioned
that this S/N is calculated for the unique mass (RIC)
determined by the software, rather than the S/N ratio in the
total ion current used in Table 2. Therefore, the number of
entries at this cut-off value were higher than in Table 2, i.e.
1034 entries were found with a S/N [200. It should be
mentioned that for some metabolites due to the oximation
two peaks can be obtained for one metabolite, so the actual
number of metabolites detected is lower than the number of
entries found.
3.2.2 RSDs of internal standards
The quantification of the internal standards was checked
and errors in the integrations were corrected manually
for both methods. The RSDs of the MS response for
the labelled internal standards were calculated for both the
GC–MS and the GC 9 GC–MS methods (Table 3). The
chromatographic performance of the GC 9 GC–MS
method was comparable or even better than that of the GC–
MS method, i.e. the RSDs of phenylalanine-d5 and glu-
tamic acid-d3 were significantly better in the GC 9 GC–
MS data compared to the GC–MS data and the other RSDs
were comparable in both datasets. These results were in
agreement with the results in Koek et al. (2008); in this
study better RSDs were obtained compared to GC–MS for
a representative set of metabolites, in addition better peak
shapes and an improved mass loadability were obtained.
3.2.3 RSDs in pooled QC samples
A set of pooled mouse-liver samples were used as QC
samples. These samples were injected at the beginning and
at the end of the sequence and between every six samples.
In total five QC samples were measured over the course of
the study. The RSDs of the MS response of target com-
pounds that were found with both 1D and 2D GC–(9GC)–
MS (total 107 targets) were compared. The RSDs for all
compared metabolites are shown in Table S1 in the
supplement.
For the majority of metabolites (70 metabolites) similar
RSDs were found with both methods (\10% difference in
RSDs), although generally the values of the RSDs for the
GC 9 GC–MS data were slightly higher than obtained
with the semi-automated GC–MS processing (Fig. 1).
However, it should be taken into account that the com-
parison is somewhat biased towards the GC–MS method.
Because the targets from the GC–MS list were searched for
in the GC 9 GC–MS data and not the other way around,
metabolites that performed well in the GC 9 GC–MS
method and were not present in the GC–MS target list or
Table 2 Number of entries in a GC–MS and GC 9 GC–MS chro-
matogram of a pooled mouse liver sample
S/N ratioa GC–MS GC 9 GC–MSb
S/N [3 435 3770
S/N [50 165 1905
S/N [100 96 1223
S/N [200 52 835
S/N [500 11 518
a Signal-to-noise ratio in the total ion current
b Number of entries obtained by deconvolution software (see text for
details) and after removal of artifacts from, i.e. solvents and reagents
(eluting at low 2tR)
Table 3 Comparing the RSDs of normalized MS responsea for the
internal standards for GC–MS and GC 9 GC–MS in all samples (QC
and study samples)
Compound RSD of MS response (%)
GC–MS GC 9 GC–MS
Alanine-d4 7 8
Leucine-d3 9 8
Glutamic acid-d3 17 8
Phenylalanine-d5 13 7
Cholic acid-d4 4 6
a MS responses of the internal standards were corrected for variations
in injection volume and MS response by normalization on the
response of dicyclohexylphthalate (used as injection standard)
Fig. 1 Comparison of RSDs for metabolites in the QC samples of
GC–MS and GC 9 GC–MS data after processing; only metabolites
detected in both methods are shown
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were not detected with the GC–MS method (due to higher
detection limits) were not evaluated in this comparision.
For six metabolites, better RSDs (differences in RSD
more than 10%) were obtained with the GC 9 GC–MS
method. For 37 metabolites poorer RSDs (differences in
RSD more than 10%) were obtained in the GC 9 GC–MS
processing. The chromatographic performance of GC 9
GC–MS was comparable when compared visually, or even
better than the performance of GC–MS; this is in agree-
ment with the comparable or even better RSD’s for the
manual corrected integration results of the internal stan-
dards (see above); the poorer RSD values for the not-
manually corrected peaks with GC 9 GC–MS were
therefore caused by errors in the data processing. Seven of
these compounds were overloaded (S-Table 1), which
resulted in split peaks in the second dimension. Obviously
these peaks will not be integrated correctly in an automated
fashion, neither in GC–MS nor GC 9 GC–MS. In the
GC–MS processing method overloaded peaks were man-
ually integrated and therefore better RSDs were obtained.
For most other peaks the higher RSDs resulted from
errors in the combining of 2D peaks belonging to the same
metabolite. For peaks to be combined the match between
the mass spectra of different modulation cycles should
meet the required match factor as set in the software.
Decreasing the match required to combine, however,
would risk combining peaks that originate from different
metabolites, especially because masses 73 ((CH3)3SiOH)
and 147 ((CH3)3SiOSi(CH3)2) are dominant masses in the
mass spectra of silylated compounds. Furthermore, in most
cases the problems with combining peaks was due to
deconvolution faults, and decreasing the match factor
would not be an option in these cases. For nine compounds
isomeric interferences of a close eluting peak was the cause
of the combination error (S-Table 1). Due to the nature of
the derivatization, two distinct compounds are formed for,
for example, sugars and sugar-phosphates (cis- and trans-
oxime forms). These two forms of one sugar elute close
together in the first dimension and posses identical mass
spectra. In these cases the chance of wrong assignment of
the identity or mistakes in the combination of second
dimension peaks is high. Another obstacle that impaired
the quantification of seven metabolites was the assignment
of the unique mass in the mass spectrum by the Chroma-
TOF software. For these compounds the non-selective
masses m/z 73 or m/z 147 were assigned as unique masses,
while these masses are present in all mass spectra of sily-
lized compounds. Due to interferences of (partly) coeluting
compounds the integration of these metabolites was inac-
curate. In principle, the masses used for quantification of
these metabolites can be manually adjusted in the cali-
bration table, and these mistakes can probably be avoided
by selecting a more selective mass instead of m/z 73 or m/z
147. However, this requires extra time to check all auto-
matically chosen quantification masses in the calibration
table.
In summary, 70 metabolites were quantified correctly
and 37 metabolites were quantified less accurately with the
semi-automated GC 9 GC–MS data processing method
compared to the semi-automated GC–MS processing. For
seven of the less-accurately quantified peaks the cause for
the less good quantification could not be attributed to the
ChromaTOF software, but to overloading effects. Thus, the
semi-automated GC 9 GC–MS data processing method
worked for 70% of the evaluated metabolites as good as the
manually corrected GC–MS reference method.
3.2.4 Summary on GC 9 GC–MS data quality
The goal in this study was to assess the feasibility of using a
processing strategy based on commercially available soft-
ware (i.e. ChromaTOF software, LECO) for the unbiased,
non-target semi-automated quantification of as many
metabolites as possible in mouse liver samples measured
with GC 9 GC–MS. The RSDs of the MS response for all
entries were calculated in the QC samples. In Fig. 2 an
overview of the amount of entries per RSD-range is given
for both GC–MS and GC 9 GC–MS. In the GC 9 GC–MS
Fig. 2 Overview of the number
of entries in the QC samples per
RSD-range for GC–MS and
GC 9 GC–MS
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data, using a non-targeted approach, still 224 entries fit
the strict FDA requirements for targeted analysis in bio-
analysis (RSD \15%) (U.S. Department of Health and
Human Services et al. 2001), compared to 116 entries from
the GC–MS data. This illustrates the added value of
GC 9 GC–MS compared to GC–MS. In addition, the
entries with higher RSDs still contain useful information,
when the differences between the compared groups of
samples are larger than the analytical variation, as illus-
trated below (cf. Sect. 3.3).
3.3 Application
The aim of the GC(9GC)–MS study was to investigate the
influence of a high fat diet on the metabolite profiles in the
liver. A total of 24 mouse liver samples, i.e. t = 0 weeks
(n = 8), t = 6 weeks (n = 8) and t = 12 weeks (n = 8)
after the start of the high fat diet, were measured with
GC 9 GC–MS and GC–MS. Development of insulin
resistance was monitored in individual mice over time by
performing glucose tolerance tests and measuring specific
biomarkers in plasma, and hyperinsulinemic-euglycemic
clamp analysis to assess insulin resistance in a tissue-spe-
cific manner as described by Kleemann et al. (2010). After
6 weeks the mice had developed insulin resistance in the
liver and after 12 weeks also in skeletal muscle and fat
tissue (white adipose tissue).
With GC 9 GC–MS many more compounds were
measured than with GC–MS. Typical chromatograms of a
mouse liver sample measured with GC–MS and
GC 9 GC–MS are shown in Figs. 3 and 4. A total of 170
and 691 metabolites were quantified with GC–MS and
GC 9 GC–MS, respectively, and analyzed using PCA and
PCDA. First, the peaks that were present in the GC–MS as
well as in the GC 9 GC–MS data set, hereafter referred to
as overlap data, were analyzed with PCA (Fig. 5) and
PCDA (Figure S-1, cf. Supplement). The first principal
component (PC1) in PCA and the first linear discriminant
(LD1) in PCDA mostly explained the variance between the
t = 0 samples and the t = 6 and t = 12 samples, PC2
(PCA) and LD2 (PCDA) explained some of the variance
between t = 0 and t = 12 compared to t = 6 weeks. As
can be seen from Fig. 5 the results from both overlapping
data sets were very comparable and the groups of mice
from the different time points were rather well separated.
The mahalanobis distances, i.e. a measure for the separa-
tion of the groups taking into account the spreading of the
samples within one group, were calculated in the overlap
data after PCA analysis (Mahalanobis 1930) (Table 4); the
distances between the t = 0 (baseline) and the high-fat-diet
treated groups in the GC 9 GC–MS data was clearly
improved, only the separation of the t = 6 and t = 12
groups was slightly better in de GC–MS data set. Fur-
thermore, more than ten metabolites that were found in the
top 20s of metabolites with the highest loadings in the GC–
MS and GC 9 GC–MS data in PCDA (LD1 and LD2, data
not shown), were the same for both data sets indicating the
similarity of the two overlapping data sets. Consequently,
although the RSDs of responses for the metabolites in the
10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00 55.00 60.00
1e+07
2e+07
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4e+07
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7e+07
8e+07
9e+07
1e+08
1.1e+08
Time-->
TIC: VP9101.D\data.ms
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500000
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2000000
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3000000
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Time-->
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TIC: VP9101.D\data.ms
AbundanceFig. 3 Total-ion GC–MS
chromatogram of a pooled
mouse-liver sample
Fig. 4 Two-dimensional colour plot of a total ion GC 9 GC–MS
chromatogram of a pooled mouse liver sample
Semi-automated non-target processing in GC 9 GC–MS metabolomics analysis 9
123
GC 9 GC–MS data were somewhat higher than in the
GC–MS data, the biological information was preserved and
even a slightly better group separation was obtained.
In Fig. 6 the result of the PCA analysis of the additional
entries from the GC 9 GC–MS data set (all entries minus
overlap entries) compared to the GC–MS data set is shown
(PCDA is shown in supplement Figure S-2). Again, the
groups of mice from different time points were rather well
separated, indicating the biological relevancy of the addi-
tional peaks in explaining the differences between the three
groups, i.e. these additional metabolites contain informa-
tion on the differences in metabolic profiles during the
development of insulin resistance. It should be mentioned
that 170 entries were detected in GC–MS and only 107 of
these metabolites were assigned in the GC 9 GC–MS data
set. The remaining 63 entries in GC–MS, except for a
maximum of six high boiling compounds (Mwunderivatized
[600), are probably also present in the GC 9 GC–MS
data set. However, these metabolites could not be unam-
biguously assigned, as no reference standards were avail-
able and/or their mass spectrum were not unique. As the
first dimension column in GC 9 GC was a polar BPX50
column rather than an apolar DB5 column used for the
GC–MS, the elution order and retention times differed for
the first dimension separation, and retention times could
not be used to identify metabolites found with one method
in the other method.
The added value of GC 9 GC–MS is also demonstrated
when the top 20 metabolites with the highest loadings in
PCDA (LD1) of the total GC–MS and the total GC 9 GC–
MS data set are compared (Table 5). Most of the metab-
olites with high loadings in LD1 of GC–MS data are found
in the top 20 LD1 of GC 9 GC–MS (bold in Table 5) or
are slightly lower ranked with still good loadings (italics in
Table 5). With GC 9 GC–MS, in LD1 of the PCDA
model many additional metabolites with high loadings
were found. Only in a few cases the metabolites of the top
20 of GC–MS ranked lower due to poorer repeatability
(i.e. 1-palmitoyl-sn-glycero-3-phosphocholine and glu-
conic acid); actually, a few metabolites (e.g. taurine and
tyrosine) ranked within the top 20 of GC 9 GC–MS and
not in the top 20 of GC–MS due to better performance
with GC 9 GC–MS. In summary, the GC 9 GC–MS
analysis provides many additional possible biomarkers for
the development and progression of insulin resistance.
In Fig. 7 the box plots of the relative response of some
high-ranked metabolites from the PCDA analysis of the
GC 9 GC–MS data are shown; these metabolites could
provide more insight in the metabolic processes involved in
the development and progression of insulin resistance
-0.8 -0.6 -0.4 -0.2 0 0.2 0.4 0.6
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
PC 1 (26.5 %)
score plot autoscaled data GCxGC
PC
 2
 (1
3.2
 %
)
T0
T6
T12
-0.8 -0.6 -0.4 -0.2 0 0.2 0.4 0.6
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
PC 1 (35.1 %)
score plot autoscaled data gc 1d
PC
 2
 (1
4.8
 %
)
T0
T6
T12
BA
Fig. 5 PCA analysis of the
overlap data (107 entries) for
GC–MS (a) and GC 9 GC–MS
(b) of mouse liver after 0 (red,
?), 6 (blue, D) and 12 (green,
d) weeks (Color figure online)
Table 4 Mahalanobis distances in the overlap data after PCA
analysis of GC–MS and GC 9 GC–MS
Groups Mahalanobis distance between groups
GC–MS GC 9 GC–MS
t = 0 and t = 6 weeks 36 47
t = 0 and t = 12 weeks 44 74
t = 6 and t = 12 weeks 13 10
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Fig. 6 PCA analysis of additional entries (compared to GC–MS; 584
peaks) in GC 9 GC–MS of mouse liver after 0 (red, ?), 6 (blue, D)
and 12 (green, d) weeks (Color figure online)
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caused by a high fat diet. For example, the campesterol
concentrations (Fig. 7, compound A) were significantly
lowered after 6 and 12 weeks of high fat diet. Campesterol
is a phytosterol, i.e. a steroid derived from plants, which is
known for its cholesterol-lowering properties when used as
a food additive (de Graaf et al. 2002). Moreover, a low
campesterol/sistosterol ratio in serum and liver has been
associated with severe liver damage and liver transplanta-
tion in primary bilairy cirrhosis (Nikkila et al. 1992a, b).
In addition, the relative responses of metabolites B, C
(linoleic acid), D (Fig. 7) and arachidonic acid were sig-
nificantly lower after 6 and 12 weeks of high fat diet;
metabolites B and D were only present in low concentra-
tions and probably therefore not detected with GC–MS.
These metabolites were all poly-unsaturated fatty acids that
are considered beneficial for health (Buckley and Howe
2009; Furuhjelm et al. 2009; Panza et al. 2009; Yaqoob
2009). Lowered levels of these metabolites are associated
with an increased risk of inflammation and promotion of
subacute chronic inflammation in metabolic disorders,
which is again related to the development of obesity and
insulin resistance (Cai et al. 2005; Verschuren et al. 2009).
Furthermore, our results are consistent with the observed
elevated levels of hepatic inflammation markers determined
in plasma of the mice used herein as well as the observed
increased activity of intrahepatic proinflammatory tran-
scription factors such as NFkB in liver biopsies adjacent to
the ones used for the present study (Kleemann et al. 2010).
Finally, the relative responses of tyrosine, spermidine
(Fig. 7, compounds E and F) and beta-alanine were lower in
the groups of mice sacrificed at t = 6 weeks and
t = 12 weeks, while the level of taurine was significantly
increased. The levels of amino acids are known to fluctuate
during the development of insulin resistance (Huffman et al.
Table 5 Top 20 metabolites with highest loading in LD1 in PCDA analysisa
Rank PCDA GC 9 GC–MS GC–MS
Compoundb Loading LD1 Compound Loading LD1
1 Campesterol* -4.41 Campesterol* -4.55
2 M0617 (unsaturated fatty acid methyl ester) -4.36 GA0502 -4.37
3 M0480 -4.29 1,2-Diglyceridec 4.28
4 M0071 -4.27 1-Palmitoyl-L-alpha-lysophosphatidic acidc -4.22
5 Linoleic acid* -4.17 1-Palmitoyl-sn-glycero-3-phosphocholine -4.18
6 M0535 (purine) -4.04 Arachidonic acid* -4.03
7 Taurine* 4.00 Linoleic acid* -4.00
8 Tyrosine* -3.99 GA0123c -3.91
9 M0221 (amino-organic acid) -3.98 Beta-Alanine -3.83
10 M0444 -3.92 GA0514 -3.82
11 M0651 -3.91 GA0510 -3.81
12 M0593 (monoglyceride) -3.90 C20:1 fatty acidc 3.80
13 Spermidine* -3.85 Pipecolinic acidc -3.78
14 M0182 (piperidine) -3.84 Fumaric acid -3.77
15 M0550 -3.84 1-Monolinoleoylglycerol -3.77
16 M0283 (pyrrolidinone) -3.81 1-Monooleoylglycerol* 3.76
17 1,5-Anhydro-D-glucitol* -3.80 Gluconic acid* -3.75
18 M0600 (polyunsaturated fatty acid) -3.79 GA0520c -3.71
19 M0597 -3.75 GA0507 -3.71
20 M0307 (deoxyglucose or isomer) -3.72 Spermidine* -3.70
a In bold: metabolites present in both top 20s, in italics: metabolites present in both datasets, but not the top 20 of GC 9 GC–MS data.
Metabolites marked with an asterisk are identified with authentic standards, other metabolites given a name are annotated via their mass spectra
(more information in Sect. 2). The retention times and quantification masses of unknowns (M-coded and GA-coded metabolites) are listed in the
Supplement (S-Table 2)
b Tentative annotation via MS library match or characterization of type of metabolite based on the mass spectrum are given in brackets
c Metabolites were not identified in the GC 9 GC–MS data set, most likely due to uncertainty in the assignment of the identity (no reference
standard available and mass spectrum not unique enough). Only number 3 and 4 from GC–MS were not measured with GC 9 GC–MS, because
their elution temperature was too high. Most probably all other metabolites are present in the 2D data set, but under a different name (M-code).
However, none of the unknown top 20 metabolites from the GC–MS data set were present in the top 20 of the GC 9 GC–MS data (checked
manually via mass spectra)
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2009; Wijekoon et al. 2004). Interestingly, taurine was
suggested to have beneficial effects by its ability to reduce
intracellular oxidative stress generation and glycooxidation
(Anuradha 2009), while this is the only metabolite in the
GC 9 GC–MS PCDA top 20 that was significantly ele-
vated in the animals after 6 and 12 weeks of high-fat diet.
Furthermore, it is believed that certain amino acids play an
important role in the development of diabetes and that
dietary treatment with amino acids could prevent diabetes
and diabetic complications (Anuradha 2009).
In conclusion, the added value of GC 9 GC–MS com-
pared to GC–MS is clearly illustrated in this pre-clinical
study. Although the RSDs of compounds in the QC sam-
ples for GC 9 GC–MS were somewhat higher than in the
GC–MS data, the biological information in the data was
preserved. In addition, many more candidate biomarkers
were detected that were significant in explaining the dif-
ferences between the different sample groups in this study.
Furthermore, the higher peak capacity resulted in cleaner
mass spectra, facilitating the identification of possible
biomarkers. Moreover, the position of the metabolite in the
chromatogram (especially the 2rT) can also aid in the
identification process (data not shown).
3.4 Concluding remarks
The feasibility of semi-automated non-target processing of
GC 9 GC–MS data using commercially available software
was assessed. A set of mouse liver samples was measured
with GC–MS and GC 9 GC–MS and a total of 170 and 691
peaks, respectively, were quantified. The performance of the
two methods was compared by evaluating the RSD values in
the quality-control samples of metabolites present in both
datasets. Although the chromatographic performance was
comparable or even slightly better for GC 9 GC–MS, as
demonstrated for the manually integrated labelled internal
standards, somewhat poorer RSDs for the relative responses
of peaks determined in a semi-automated manner due to less
accurate processing. Still a reliable and repeatable quanti-
fication was obtained for approximately 70% of the peaks,
even though the integrations of the peaks from the
GC 9 GC–MS data were not manually corrected in contrast
with the GC–MS data.
In addition, GC 9 GC–MS processing is time-consum-
ing, the major bottleneck being the speed of the software
tools and algorithms. However, application of the strategy
described in this paper is feasible for small studies with a
maximum of about 30–50 samples (eventually measured in
duplicate). For the routine application of GC 9 GC–MS in
metabolomics in larger studies, further improvement of
data processing tools is required.
The mouse-liver samples were measured to study the
development and progression of insulin resistance. The
added value of GC 9 GC–MS was clearly illustrated, (i)
over four times more peaks could be quantified, (ii) the
biological information as acquired in GC–MS was pre-
served, (iii) several extra candidate biomarkers for the
development of insulin resistance were found, and (iv) the
superior peak capacity resulted in cleaner mass spectra,
facilitating in principle the putative identification of
metabolites.
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